TransMedics reported a Q2 earnings beat mainly due to gains in low-margin logistics and pricing rather than increased organ transplants on its platform. Revenue growth was concentrated in liver transplants, which make up 78% of organ revenue, while heart growth was minimal and lung revenue declined 42% year-over-year. Key growth drivers for heart and lung transplants, the ENHANCE and DENOVO programs, are delayed by FDA enrollment issues and currently contribute little while reducing margins. Adjusted operating margins have declined, and the company only modestly raised its full-year guidance. Despite these challenges, TransMedics still trades at a high valuation of about 45 times forward earnings, reflecting expectations for high-margin growth that may be optimistic given current results.
Rosen Law Firm has announced an investigation into potential breaches of fiduciary duties by the directors and officers of TransMedics Group, Inc. This move could impact shareholders as it suggests possible mismanagement or misconduct at the company....
TransMedics Group reported a 21% increase in total revenue to $189.9 million for Q2 2026, driven by higher usage of its Organ Care System and logistics services. Despite a net income decline to $14.7 million due to increased operating expenses from s...
TransMedics Group, a medical tech company specializing in organ transplant therapy, granted 18,762 stock options and 12,414 restricted stock units to 9 new employees on July 29, 2026. These grants serve as inducements for employment and were approved...
